February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: Discovering Complex Clinical and Pathological Features

Virtual 2021 International Conference on Alzheimer’s & Parkinson’s Diseases

Utilizing Biomarkers to Facilitate a Differential Diagnosis: What Lies Beneath

Oscar Lopez, MD, FAAN, discusses the utility and value of biomarker assessments in distinguishing Alzheimer’s disease from other dementia etiologies. He presents the MRI, CSF, and PET biomarker profiles of several dementia etiologies, and he uses the patient case study to demonstrate how these assessments can help to inform a diagnosis of Alzheimer’s disease in cases with mixed pathologies. Furthermore, Dr. Lopez and the panel discuss recent advancements in plasma biomarkers and the prospect for the implementation of these tools in clinical practice.

Key Learning Objectives for Biogen’s ADPD 2021 Symposium:

  • Understand how mixed pathologies and varying clinical presentations can affect the early diagnosis of Alzheimer’s disease
  • Gain insights into how comprehensive cognitive assessment tools and fluid and imaging biomarkers can be used to achieve an early diagnosis of Alzheimer’s disease in challenging cases with mixed pathologies
  • Assess the current healthcare system readiness for timely diagnosis of Alzheimer’s disease and management of patients

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.